Many patients, including three Long Island -based lawyers representing customers such as New York and New Jersey, claim that they suddenly lost their vision after taking the popular weight loss drugs Ozempic and WEGOVY.
This suspicion occurs in several studies showing the connection between the vice -vision complications and the active ingredients of the ozempic, Wegovy, and Rybelsus, or the activity of the activity of the mounjaro and zepbound.
Litigation pursues untimled financial damages.
‘They can’t be completely seen’
Jason Goldstein, a senior lawyer for Parker Waichman LLP, who represents more than 12 customers, including two people from Nassau County, claims to lose vision after taking Ozempic or Wegovy after taking Ozempic or WEGOVY. I insisted. Eyes -after taking drugs containing half glue.
What Newsday found
- Port Washington Lawyer After taking a popular weight loss drug, the customer suddenly suddenly filed more than 12 lawsuits that lost their vision.
- Recent pairs of research Semaglutide and Tirzepatide show the potential connection between the active ingredients of many weight loss drugs and the stroke of the eye.
- Novo Nordic, Manufacturers of Ozempic and Wegovy argue that vision loss is not considered a potential side effect on drugs containing half glue.
Goldstarin has filed a lawsuit in Novo Nordisk, a manufacturer of Ozempic and Wegovy, in MiddleSex, New Jersey, and said he plans to submit others in the next few weeks.
NAION is rare, up to 10 out of 100,000 people in the general population, researchers said.
Goldstein said, “People just wake up and develop this NAION status. …” they wake up and can’t see it completely. Many people lose their surroundings. They can lose overall vision. I lost it from both eyes to one customer. “
His customer includes Edward Fanelli (57), a 57 -year -old freeHold of New Jersey, who prescribed Ozempic for the treatment of type 2 diabetes in October 2022. About eight months later, Fanelli said he developed a seriously blurry vision on his right eye, was diagnosed with NAION, and had to stop working as a general contractor.
In the interview, Fanelli said that if you know the potential risk of vision loss, you would never have taken the drug.
“If I was on the label, I wouldn’t have taken it,” said Fanelli. “Who is dangerous to lose your eyesight?”
Lauren Browdy Weiner, a spokesman for Novo Nordisk, said in a statement that Naion is not considered a potential side effect on drugs containing semaglutide.
“Novo Nordisk has the opinion that Semaglutide’s benefits of risk profiles do not change,” Weiner added. Internal research added that it does not propose “causal relationship” between Semaglutide and NAION. … “Patient safety is the top priority of Novo Nordisk, and we are very serious about all reports on side effects of drug use.
I needed further research
no way January study He was published in Jama Ophthalmology and reviewed nine patients between 37 and 77 years of age, written by Dr. Bradley Katz, professor of ophthalmology and visual science at Utah University.
Injectable weight loss drug Wegovy can be found on April 24, 2024 from New City Halstead Pharmacy in Chicago. Credit: TNS/Scott Olson
The study was found to have experienced naion by seven subjects, one of which was known as papillary nerve inflammation, and the other developed a paracentered acute intermediate macular disease, which is a condition in which individuals experience blind spots in the vision.
Katz, an ophthalmologist at John A. Moran Eye Center, said that the rapid change of blood sugar could not suggest that the patient would stop taking the drug, but could contribute to vision complications.
Katz said, “This review was not carried out in a way that we could say that this drug caused complications.” “To test our hypothesis, further research is needed. But this is an important issue for ophthalmologists when monitoring the use of these drugs and monitoring how to communicate best with patients.”
Meanwhile, A study In July, the Boston -based Mass Eye and Ear analyzed the medical records of more than 17,000 patients. Researchers have found that diabetics prescribed in semagluide are more than four times more likely to be diagnosed with NAION.
In the statement last year, in the statement, “Our research results should be considered important but tentative because we need future research to investigate these questions in much larger and more diverse population to investigate these questions in much larger and more diverse population.
The USA and Academy in San Francisco said that there is not enough data for patients to stop taking weight loss drugs.
Dr. Andrew Lee said, “It is premature to conclude that the association is a causal association,” said Dr. Andrew Lee, headquartered in Houston. “To test the hypothesis, more research is needed. Until then, the patient knows this information, and consults with the nursing team to choose carefully and select information according to individual risk profiles.”
Modification: Long Island law companies represent more than 12 customers who claim to have lost vision after taking weight loss drugs, and have filed a lawsuit so far. The previous version of this article misused the company’s number lawsuit.
Robert Brodsky is a Breaking News journalist who has been working at NewSday since 2011. He is Queens College and American University Alum.
